SCHEMBL30891337

O=C(CCCCCNC(=O)[C@H](CCC(=O)NCCCC[C@@H](C(=O)NCCO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O)N(CC(=O)NCCO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O)CC(=O)NCCO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O)NC(=O)OCc1ccccc1)NCCO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O

nearest known ligand 0.53

Predicted protein targets (top 8)

	gene	UniProt	supporting neighbours	confidence
▸	SIRT2	Q8IXJ6	10/20	0.50

▸	TPSAB1	Q15661	2/20	0.43

▸	SIRT1	Q96EB6	8/20	0.43

▸	SIRT3	Q9NTG7	7/20	0.43

▸	EPOR	P19235	3/20	0.42

▸	PTGER4	P35408	2/20	0.41

▸	CAPN1	P07384	1/20	0.41

▸	CAPN2	P17655	1/20	0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL30891474	0.97	SIRT2 (0.47)	SIRT2TPSAB1SIRT1SIRT3EPOR
SCHEMBL30891392	0.96	SIRT2 (0.48)	SIRT2TPSAB1SIRT1SIRT3EPOR
SCHEMBL30891440	0.96	SIRT2 (0.48)	SIRT2TPSAB1SIRT1SIRT3EPOR
SCHEMBL30891345	0.95	FOLH1 (0.45)	SIRT2SIRT1EPORCAPN1CAPN2
SCHEMBL23519139	0.95	SIRT2 (0.58)	SIRT2SIRT1SIRT3
SCHEMBL23497291	0.95	FOLH1 (0.46)	SIRT2EPORPTGER4
SCHEMBL23497293	0.95	FOLH1 (0.46)	SIRT2EPORPTGER4
SCHEMBL30891353	0.95	SIRT2 (0.43)	SIRT2SIRT1EPORCAPN1CAPN2
SCHEMBL30891423	0.93	SIRT2 (0.45)	SIRT2TPSAB1SIRT1SIRT3EPOR
SCHEMBL30891310	0.93	SIRT2 (0.45)	SIRT2TPSAB1SIRT1SIRT3EPOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20260021190-A1	GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES	MERCK SHARP & DOHME LLC (US)	2026-01-22	—	—	US	disclosed
EP-4615487-A1	GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES	Merck Sharp & Dohme LLC (US)	2025-09-17	—	—	EP	disclosed
WO-2024102633-A1	GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES	MERCK SHARP & DOHME LLC (US)	2024-05-16	—	—	WO	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20260021190-A1	GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES	INSR, GPR119, GLP1R	SIRT2 836/4885TPSAB1 807/4885SIRT1 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.